Understanding the involvement of proinflammatory cytokines in heart failure may enable future therapies using monoclonal antibodies to block disease progression.
Answers are grounded in this paper and cite their sources.
May inform anti-cytokine monoclonal antibody trials in heart failure; leaves open clinical efficacy.
Heart failure is a complex neurohumoral and inflammatory syndrome. Recent studies have shown that proinflammatory cytokines (interleukin-1, interleukin-2, interleukin-6, interleukin-10, and tumor necrosis factor) are involved in cardiac depression and in the complex syndrome of heart failure. Understanding the involvement of these cytokines may enable us to reverse cardiac depression and heart failure by the use of monoclonal antibodies directed against specific cytokines to block the downhill progression of heart failure.
No takes yet. Share an insight, caveat, or question.
Blum et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: